ADMA Biologics (NASDAQ:ADMA) Trading 6.4% Higher – Here’s What Happened

ADMA Biologics Inc (NASDAQ:ADMA) shares traded up 6.4% during mid-day trading on Tuesday . The company traded as high as $8.39 and last traded at $8.3840. 3,932,853 shares traded hands during mid-day trading, a decline of 29% from the average session volume of 5,554,766 shares. The stock had previously closed at $7.88.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on ADMA shares. Zacks Research downgraded shares of ADMA Biologics from a “strong-buy” rating to a “hold” rating in a report on Monday, April 27th. Wall Street Zen downgraded shares of ADMA Biologics from a “buy” rating to a “hold” rating in a report on Monday, May 4th. Canaccord Genuity Group dropped their target price on shares of ADMA Biologics from $21.00 to $18.00 and set a “buy” rating for the company in a report on Thursday, May 7th. Mizuho dropped their target price on shares of ADMA Biologics from $24.00 to $20.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Finally, Cantor Fitzgerald restated a “neutral” rating on shares of ADMA Biologics in a report on Thursday, March 26th. Two equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $19.00.

ADMA Biologics Trading Up 8.0%

The stock has a market cap of $2.03 billion, a P/E ratio of 12.55 and a beta of 0.83. The firm’s 50 day simple moving average is $11.83 and its two-hundred day simple moving average is $15.38. The company has a quick ratio of 3.93, a current ratio of 6.95 and a debt-to-equity ratio of 0.51.

ADMA Biologics (NASDAQ:ADMA) last issued its earnings results on Wednesday, May 6th. The biotechnology company reported $0.19 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.19. ADMA Biologics had a return on equity of 39.98% and a net margin of 32.43%.The company had revenue of $114.49 million for the quarter, compared to the consensus estimate of $139.98 million. During the same quarter in the prior year, the company earned $0.11 EPS. The firm’s quarterly revenue was down .3% on a year-over-year basis. As a group, equities research analysts predict that ADMA Biologics Inc will post 0.84 earnings per share for the current fiscal year.

Insider Buying and Selling at ADMA Biologics

In related news, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of ADMA Biologics stock in a transaction dated Monday, March 9th. The stock was sold at an average price of $15.63, for a total value of $157,800.48. Following the completion of the transaction, the chief operating officer directly owned 466,600 shares of the company’s stock, valued at $7,292,958. The trade was a 2.12% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Steve Elms purchased 7,000 shares of the business’s stock in a transaction that occurred on Thursday, March 5th. The stock was acquired at an average cost of $15.67 per share, with a total value of $109,690.00. Following the completion of the acquisition, the director directly owned 2,038,730 shares of the company’s stock, valued at $31,946,899.10. The trade was a 0.34% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Company insiders own 3.90% of the company’s stock.

Institutional Investors Weigh In On ADMA Biologics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Summit Securities Group LLC acquired a new stake in ADMA Biologics during the 4th quarter valued at $29,000. Rothschild Investment LLC increased its position in ADMA Biologics by 373.8% during the 3rd quarter. Rothschild Investment LLC now owns 1,895 shares of the biotechnology company’s stock worth $28,000 after buying an additional 1,495 shares during the period. Optima Capital LLC acquired a new stake in shares of ADMA Biologics during the 4th quarter worth $36,000. Clearstead Advisors LLC grew its holdings in shares of ADMA Biologics by 55.7% during the 3rd quarter. Clearstead Advisors LLC now owns 2,222 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 795 shares in the last quarter. Finally, iSAM Funds UK Ltd acquired a new stake in ADMA Biologics in the third quarter valued at about $34,000. Institutional investors own 75.68% of the company’s stock.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.